title: The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels.
abstract: BACKGROUND
  Coronary artery disease (CAD) of allografted hearts is the main cause of late mortality after cardiac transplant, but its etiology is still undetermined.
  
  
  OBJECTIVE
  This study was undertaken to evaluate the relevance of several risk factors, including cyclosporine (CsA) dose and blood CsA levels, to the incidence of CAD.
  
  
  METHODS
  In 163 heart transplants performed between November 1985 and August 1994 at our Institution, CAD was diagnosed by coronary angiography or at postmortem examination. Patients in whom postmortem examination or coronary angiography was not performed, as well as those < 15 years of age and those who died within 1 month of surgery, were excluded from the study. The following risk factors were analyzed: recipient age, gender, pretransplant diagnosis, donor age, number of human leukocyte antigen (HLA)-AB mismatches, cytomegalovirus serology, mear serum cholesterol and triglyceride levels, the number of treated acute rejections, mean weighted CsA dose (CsA dosew and weighted blood CsA levels (blood CsA levelw).
  
  
  RESULTS
  Coronary artery disease was diagnosed in 32 patients (19.6%). A low mean CsA dosew was the only significant predictor for CAD at multivariate analysis (p < 0.01): there was no correlation with blood CsA levelw. In the patients receiving a CsA dosew > 4 mg/kg/day, the 8.9 year probability of their remaining CAD free was 69% [confidence interval (CI) 50-87%] in comparison with 31% (CI 0-65%) in patients receiving a CsA dosew < 4 mg/kg/day.
  
  
  CONCLUSIONS
  In our experience, a low CsA maintenance dose is the main risk factor for CAD, irrespective of blood CsA levels.
authors.affiliation: Department of Cardiac Surgery, Ospedali Riuniti di Bergamo, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Gamba
authors.forename: F
authors.initials: F
authors.lastname: Mamprin
authors.forename: R
authors.initials: R
authors.lastname: Fiocchi
authors.forename: M
authors.initials: M
authors.lastname: Senni
authors.forename: G
authors.initials: G
authors.lastname: Troise
authors.forename: P
authors.initials: P
authors.lastname: Ferrazzi
authors.forename: R
authors.initials: R
authors.lastname: Ferrara
authors.forename: G
authors.initials: G
authors.lastname: Corbetta
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003327:Coronary Disease / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D016572:Cyclosporine / Q000008:administration & dosage* / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000097:blood* / Q000175:diagnosis / Q000517:prevention & control; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000097:blood; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine